{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/652558c78b631000124f5568/69b7d5d6559de2c63424cee1?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"HS Management: Combining surgery and medical treatments ","description":"<p>This&nbsp;podcast&nbsp;is aimed at healthcare professionals, produced and funded by UCB.&nbsp;&nbsp;</p><p><br></p><p>Episode 2&nbsp;brings together two&nbsp;surgical experts – our host,&nbsp;Prof Monika&nbsp;Arenbergerová&nbsp;and&nbsp;Prof Eva&nbsp;Vilarrasa. Together, they discuss the evolution of the use of surgery in HS, the use of biological treatments, and how we can combine both surgical and medical management of HS to improve outcomes.&nbsp;&nbsp;</p><p>HS: Hidradenitis Suppurativa&nbsp;</p><p><br></p><p><em>Prof Monika&nbsp;Arenbergerová&nbsp;has received support from UCB, AbbVie, and Novartis.</em>&nbsp;</p><p><br></p><p><em>Prof Eva&nbsp;Vilarrasa&nbsp;has received research support, speaker/consultant fees and honoraria, and served as an advisory board member for&nbsp;AbbVie,&nbsp;Acelyrin, Almirall, Amgen, Bayer,&nbsp;Biofrontera&nbsp;AG, Boehringer Ingelheim, Bristol&nbsp;Myers Squibb, Celgene, Galderma,&nbsp;Gebro&nbsp;Pharma, Incyte, ISDIN, Johnson&nbsp;&amp;&nbsp;Johnson, Leo&nbsp;Pharma,&nbsp;Eli-Lilly, Merck&nbsp;Serono,&nbsp;MoonLake&nbsp;Immunotherapeutics, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB,&nbsp;iDermApp,&nbsp;Mediktor,&nbsp;Dermus&nbsp;Pharma,&nbsp;BIOMI Life Sciences,&nbsp;HSCalc, and Barcelona Health Hub.</em>&nbsp;</p><p><br></p><p>&nbsp;</p>","author_name":"UCB Biopharma"}